基石藥業(02616.HK)發布產品臨床研究數據
基石藥業(02616.HK)公布,於歐洲消化腫瘤協會胃腸道腫瘤2021線上年會上,以口頭短報告形式公布其產品「泰吉華」就中國胃腸道間質瘤晚期患者的I/II期臨床研究數據。
公司指,是次研究結果發布將為相關患者的治療帶來新的研究證據,並有助改善臨床實踐。報告指,泰吉華對攜帶PDGFRA D842V突變的中國胃腸道間質瘤患者展示出優越和持久的抗腫瘤活性,對四線及以上的胃腸道間質瘤患者亦展示出治療潛力。另外,泰吉華在中國胃腸道間質瘤患者人群中安全性和耐受性良好,與全球其他研究結果一致。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.